ASX ANNOUNCEMENT

Actinogen AGM – Chair's address and CEO's presentation

Sydney, 16 November 2022. Actinogen Medical ASX: ACW ("ACW" or "the Company") is pleased to release the Chair's address and CEO's slide presentation to this morning's Annual General Meeting commencing at 11am (AEDT) in Sydney.

The AGM will be held at the offices of K&L Gates (Boardrooms 1, 2, 3 and 4), Level 31, 1 O'Connell Street, Sydney NSW 2000, and accessible online.

Shareholders wishing to attend the AGM online will need to login to the Automic portal https://investor.automic.com.au from 10.30am (AEDT) today to obtain the virtual meeting webinar link.

The Chair's address and CEO's presentation slides are attached to this announcement.

ENDS

Investors

Dr. Steven Gourlay
CEO & Managing Director
P: +61 2 8964 7401
E. steven.gourlay@actinogen.com.au

Michael Roberts
Investor Relations
M: +61 423 866 231
E. michael.roberts@actinogen.com.au

Announcement authorised by the Board of Directors of Actinogen Medical

About Actinogen Medical

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health.

Cognitive function means how a person understands, remembers and thinks clearly. Cognitive functions include memory, attention, reasoning, awareness and decision-making.

Actinogen is currently developing its lead compound, Xanamem,® as a promising new therapy for Alzheimer's Disease and Depression and hopes to study Fragile X Syndrome and other neurological and psychiatric diseases in the future. Reducing cortisol inside brain cells could have a positive impact in these and many other diseases. The cognitive

dysfunction, behavioural abnormalities, and neuropsychological burden associated with these conditions is debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

About Xanamem

Xanamem's novel mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11β-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule.

Chronically elevated cortisol is associated with cognitive decline in Alzheimer's Disease, and Xanamem has shown the ability to enhance cognition in healthy, older volunteers. Cognitive impairment is also a feature in Depression and many other diseases. Cortisol itself is also associated with depressive symptoms and when targeted via other mechanisms has shown some promise in prior clinical trials.

The Company has studied 11β-HSD1 inhibition by Xanamem in more than 300 volunteers and patients, so far finding a statistically significant improvement in working memory and attention, compared with placebo, in healthy, older volunteers in two consecutive trials and clinically significant improvements in patients with biomarker-positive mild AD. Previously, high levels of target engagement in the brain with doses as low as 5 mg daily have been demonstrated in a human PET imaging study. A series of Phase 2 studies in multiple diseases is being conducted to further confirm and characterize Xanamem's therapeutic potential.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem® is a trademark of Actinogen Medical.

Disclaimer

This announcement and attachments may contain certain "forward-looking statements" that are not historical facts; are based on subjective estimates, assumptions and qualifications; and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements should be considered "at-risk statements" - not to be relied upon as they are subject to known and unknown risks, uncertainties and other factors (such as significant business, economic and competitive uncertainties / contingencies and regulatory and clinical development risks, future outcomes and uncertainties) that may lead to actual results being materially different from any forward looking statement or the performance expressed or implied by such forward looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Actinogen Medical does not undertake any obligation to revise such statements to reflect events or any change in circumstances arising after the date hereof, or to reflect the occurrence of or non-occurrence of any future events. Past performance is not a reliable indicator of future performance. Actinogen Medical does not make any guarantee, representation or warranty as to the likelihood of achievement or reasonableness of any forward-looking statements and there can be no assurance or guarantee that any forward-looking statements will be realised.

ACTINOGEN MEDICAL ENCOURAGES ALL CURRENT INVESTORS TO GO PAPERLESS BY REGISTERING THEIR DETAILS WITH THE DESIGNATED REGISTRY SERVICE PROVIDER, AUTOMIC GROUP.

16 November 2022

ACW 2022 AGM Chair's Address

On behalf of the Board of Directors and staff of Actinogen Medical Ltd, I welcome you to our 2022 Annual General Meeting.

I am pleased to report that Actinogen has performed extremely well throughout the past year, with several outstanding achievements and significant milestones.

This is even more admirable in the context of the COVID-19 pandemic and the difficult market conditions of recent times. Despite the COVID impact on clinical development in the worldwide healthcare industry, we have managed extremely well with our proactive, hands-on approach to clinical trials.

Our first major clinical milestone for the year was the replication and confirmation of the cognitive enhancing properties of our lead molecule, Xanamem®, at 5 mg and 10 mg dose levels in the XanaMIA Part A trial, announced in April 2022.

Then, just over a month ago, we were very pleased to announce positive Phase 2a data from our Alzheimer's Disease (AD) biomarker study, that showed a strong clinical effect from Xanamem and a major validation of the 'cortisol hypothesis' for AD.

In addition to these outstanding clinical results, we have made progress and achieved milestones in all facets of our business ranging from the launch of our new corporate brand, logo and website, through to scale-up manufacturing of the Xanamem Active Pharmaceutical Ingredient, to now developing commercial grade tablets for use in our upcoming XanaMIA Phase 2b AD trial.

Steve Gourlay and the executive team have made significant efforts to attend and participate in major international conferences and meetings during the past year. These conferences are important for keeping the Xanamem story front and centre in the biopharma industry, in particular with potential business partners.

I said last year that Actinogen was well-placed to emerge from the pandemic environment in a strong commercial and operating position for 2022 and beyond, driven by our corporate strategy and underpinned by the support of our shareholders. I'm pleased to report that statement has held true. During this time, the Company has built significant momentum in all aspects of its business and the implementation of our strategic priorities.

And that momentum is due in no small part to the leadership of Dr. Steven Gourlay who continues to excel as our CEO, successfully driving the company forward through each stage of the clinical trials program, towards the prospective commercialization of Xanamem.

® Xanamem is a registered trademark of Actinogen Medical Limited

Actinogen Medical Limited ACN 086 778 476
Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000

+61 2 8964 7401 | actinogen.com.au

Steve will speak shortly in more detail about the first-class team we are assembling, but shareholders have already seen and heard from several of the executive leadership team in corporate presentations this year, including the very informative *Clinical Trials Science Forum* held in August. If you haven't yet seen that webinar, I highly recommend that you watch the recording that's available on the company's website to deepen your knowledge about Actinogen and hear a plain-English explanation of the 'what and why' of the things we do.

We were also pleased to announce the establishment of two new Xanamem clinical advisory boards including one for Cognition and Depression. This panel of renowned global thought leaders has already provided expert guidance and advice for our upcoming trials. We recently added Singapore-based Associate Professor Chris Chen to the Depression and Cognition Advisory Board and we recognise and value the outstanding contributions that all our eminent advisors make to our clinical programs.

Steve will expand more on our advisory boards in his presentation, and details on all the Company's board, advisory board and senior executive team members can be found on the Company's website, www.actinogen.com.au,

Turning to the balance sheet, Actinogen remains in a strong financial position with $12.98 million in cash as at 30 September 2022. We added a further $4.17 million to the cash balance in mid-October 2022 through the receipt of an R&D tax incentive refund.

In December 2021 we successfully completed a $13.3 million capital raising comprising a share placement to institutional and professional investors, and a Share Purchase Plan for retail shareholders. The Board was extremely pleased with the support received from both new and current investors, which helped strengthen our financial position and allowed us to advance our clinical development pipeline.

The CEO and Non-executive Directors also demonstrated confidence in the outlook by acquiring shares in the December 2021 capital raising, as well as in approved on-market transactions during the past six months.

On corporate governance matters your Board seeks continuous improvement in its governance and management oversight capability. During the past year we conducted our periodic review of all activities and responsibilities, including the Board skills matrix to identify gaps and opportunities for improvement.

Specific outcomes this year were:

- The operation of the Audit committee, chaired by Malcolm McComas to monitor and review the integrity of the Company's financial reporting, and;

- The development of refined Key Performance Indicator (KPI) evaluation processes, that enable us to use KPIs for incentivizing employees and contractors.

We will continue to assess the skills suitable for the Board and where appropriate make changes and/or additions to its composition.

Actinogen has just completed an extremely busy and valuable year, headlined by many significant highlights and achievements. Broker analysts have been starting to publish their reviews of the Actinogen story with the issue of new reports recently, including those from Bell Potter, Edison and Spark Plus.

We will continue to fill vital organisational and technical consultant roles to drive strategic initiatives and ensure the success of our clinical development program and other operational requirements. Also, we

will continue to proactively manage all aspects of business, while working closely with existing and potential new partners to ensure the best possible outcomes for you, our shareholders, while at the same time providing hope for sufferers of conditions like Alzheimer's Disease and Depression.

I would like to thank all our dedicated staff, the executive team, our esteemed advisory boards and my fellow corporate board members for their strong contributions to the success of the Company in the past year.

The Board remains very confident about the Company's prospects in 2023 and beyond. We now enter an exciting period with the commencement within the next six weeks of the XanaCIDD Phase 2a trial in Depression and then the XanaMIA Phase 2b Alzheimer's Disease trial in the first half of calendar 2023.

On behalf of the Board, I would like to thank you, our shareholders, for your ongoing support, and we look forward to updating you on our progress during the coming year.

I will now hand over to our CEO, Steve Gourlay, to give you a snapshot of the operational highlights in his CEO report on a very successful year. Thank you.

Actinogen

Annual General Meeting 2022

De-risked and moving rapidly forward with phase 2 trials

Dr. Steven Gourlay MBBS PhD MBA, CEO & MD

16 November 2022

Authorised by the Board of Directors of Actinogen Medical Limited

Disclaimer

This presentation has been prepared by Actinogen Medical Limited. ("Actinogen" or the "Company") based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Actinogen, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Actinogen and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Actinogen is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Actinogen securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Actinogen its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Actinogen does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

This presentation is not for general distribution or third party reliance or use.

This presentation contains certain budget information, forecasts and forward looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management in respect of which there is NO guarantee of future performance. Such budget information, forecasts and forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Actinogen to be materially different from the results or performance expressed or implied by such forward looking statements. These risks and uncertainties include, but are not limited to the performance of Actinogen in its clinical trials including whether it's technology proves to be a safe and effective treatment, market penetration, competition from any other similar products, intellectual property risks (including securing rights in technology and patents) and global economic conditions. Furthermore, Actinogen's research, product development, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. There is no guarantee that Actinogen will obtain the required approvals, licences and registrations from the relevant authorities in jurisdictions in which it operates. Actinogen or others could identify product and efficacy issues relating to the safety of our technology. Accordingly, all forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which Actinogen will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. There is no guarantee that Actinogen will achieve its stated objectives/milestones, that any of its forecasts will be met or that forward looking statements will be realised. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Neither Actinogen nor any other entity or person in or associated with Actinogen guarantee any return (whether capital or income) or generally the performance of Actinogen or the price at which its securities may trade. Any investment in Actinogen is subject to investment risks including the possibility of loss of capital invested and no return of income or payment of any dividends.

To the maximum extent permitted at law, Actinogen and all of its representatives, directors, officers, partners, employees or professional advisers (Parties) exclude all direct and indirect liability arising out of or in connection with any use or reliance of the information contained or described within this presentation. Other than to the extent required by law (and only to that extent), the Parties do not make any representation or give any assurance, guarantee or warranty (express or implied) as to, nor assume any responsibility or liability for, the authenticity, origin, validity, accuracy, suitability or completeness of, or any errors in or omissions from, any information, statement or opinion contained in this presentation or any accompanying, previous or subsequent material or presentation.

Actinogen company snapshot

Actinogen Medical (ASX:ACW) is developing a novel oral treatment with rapid onset of clinical activity to improve cognition and quality of life

Favourable pharmaceutical properties

- ✓ Demonstrated target engagement in brain and HPA axis[1] in human trials
- ✓ **Low dose, ≤10mg**
- ✓ Low drug-drug interaction potential suitable for combination therapy

Substantial clinical data

- ✓ **>300 subjects or patients safely treated**
- ✓ Cognitive enhancement activity (attention & working memory) - two trials
- ✓ Large **CDR-SB effect** in pTau-positive AD of 0.6-0.8 points - Phase 2a data

Attractive disease indications and rationale

- ✓ **Strong cortisol rationale for treatment of multiple diseases**: early stages of Alzheimer's Disease; Depression & related cognitive impairment; Fragile X Syndrome; and many others

Protected and funded

- ✓ Molecule in-licensed from U Edinburgh in 2014
- ✓ Comprehensive patents in place[2]
- ✓ **Cash position ~A$17M incl. receivables at 30 Sep 2022**

High functioning semi-virtual company model

- ✓ Core team of 10 fulltime employees based in Australia
- ✓ Leveraging senior consultants in various fields in Australia, Asia, UK and USA
- ✓ **Australian-based operations gains 43.5% as cash rebate**

1. Hypothalamic-Pituitary-Adrenal axis (body's system to regulate blood levels of cortisol)
2. Composition of matter to 2031 plus 5-year extension in most countries, new patents published and in process

Xanamem: Oral, low dose, once-a-day treatment with a unique non-amyloid mechanism

Brain penetrant 11β-HSD1 small molecule enzyme inhibitor reduces cortisol inside brain cells - modulating signaling pathways and underlying disease processes[1,2]

Potential to be:

- Rapidly cognitive enhancing
- Disease-modifying (slow or halt progression) in AD
- Anti-depressant



1. Xanamem® is a CNS (Central Nervous System) penetrant small molecule based on human PET scan evidence and cerebrospinal fluid (CSF) measurements
2. Sooy et al. 2015 showing effects on amyloid plaque reduction in an aged mouse model after 28 days associated with increases in insulin degrading enzyme; Popoli et al. 2011 microglial cell modulation in rats, effects on glutamate, cannabinoid and other signalling pathways

Major price recovery to December 2021 levels

Share price chart at 15 November 2022



Trading Information

52 week high	A$0.20
52 week low	A$0.04
Number of issued shares	1,799M
Market capitalisation (14 Nov 2022)	A$216M
Cash Balance at 30 Sep 2022	A$17M[1]

Major Shareholders

BVF Partners	13.8%
Steven Gourlay	3.7%
Edinburgh Technology Fund	2.7k%



[1] Including receivable of A$4 million for R&D tax credit

Accelerating the right clinical development plans

See also Actinogen Clinical Trials Science Forum 03 August 2022

https://youtu.be/Bm9ATZx1zEk

Then and now…

2021

- ✓ XanaHES attention & working memory
- XanaMIA results pending
- Phase 2a stored biomarker samples identified

2022

- ✓ *XanaHES attention & working memory*
- ✓ *XanaMIA attention & working memory 5 & 10 mg*
- ✓ *Large CDR-SB effect seen in Phase 2a clinical biomarker study 10 mg*
- ✓ Commercial tablets in production
- ✓ First Clinical Trials Science Forum
- ✓ Enhanced team
- ✓ 2 new phase 2 trials

Cortisol hypothesis validated, entering late phase 2 with a view to commercialization

De-risked and ready…

2021

- ✓ XanaHES attention & working memory
- XanaMIA results pending
- Phase 2a stored biomarker samples identified

2022

- ✓ *XanaHES attention & working memory*
- ✓ *XanaMIA attention & working memory 5 & 10 mg*
- ✓ *Large CDR-SB effect seen in Phase 2a clinical biomarker study 10 mg*
- ✓ Commercial tablets in production
- ✓ First Clinical Trials Science Forum
- ✓ Enhanced team
- ✓ 2 new phase 2 trials

Three independent randomized trials with cognitive activity de-risks program

Phase 2b simulation …

2021

- ✓ XanaHES attention & working memory
- XanaMIA results pending
- Phase 2a stored biomarker samples identified

2022

- ✓ *XanaHES attention & working memory*
- ✓ *XanaMIA attention & working memory 5 & 10 mg*
- ✓ *Large CDR-SB effect seen in Phase 2a clinical biomarker study 10 mg*
- ✓ Commercial tablets in production
- ✓ First Clinical Trials Science Forum
- ✓ Enhanced team
- ✓ 2 new phase 2 trials

Phase 2a analysis of patients with elevated pTau is a simulation of the Phase 2b

Xanamem Phase 2 & 3 program

Building on four independent Phase 1 and 2 studies showing activity



Robust Phase 2b trial design & implementation model: selecting AD patients by blood pTau level



Key inclusion/exclusion criteria	Primary Endpoints	Key Secondary Endpoints	Key Implementation Features
• Clinical diagnosis of **MCI or mild dementia** due to AD (NIA-AA) • Elevated blood **p-tau181** • Cognitive impairment relative to demographic norms • Excluded vascular cause of dementia	• **CDR-SB** • **Cogstate CTB attentional composite** (attention and working memory)	• **Amsterdam Activity of Daily Living** scale • Cogstate **Executive Function & Episodic Memory** Function Composites • Individual tests • Carer questionnaire / Patient Global Improvement	• **Australian trial sites plus selected international locations** • **Actinogen "hands-on" operational model** • Optimized for scalable addition of international sites as required

iDSST=international Digit Symbol Substitution Test - Symbols ; IQCODE=Informant Questionnaire on Cognitive Decline in the Elderly; MCI=mild cognitive impairment; NIA-AA=National Institute of Aging - Alzheimer's Association; RBANS=Repeatable Battery for the Assessment of Neuropsychological Status;

The Xanamem opportunity in depression

Current anti-depressants

work slowly (3 weeks) and initial suicide risk

do not target cognition

multiple adverse effects
blood pressure, sexual function, appetite…

Xanamem improves cognition quickly

Xanamem may improve both depression and cognitive impairment

XanaCIDD trial design & implementation model



Key inclusion/exclusion criteria	Primary Endpoints	Key Secondary Endpoints	Key Implementation Features
• Primary diagnosis of **MDD** • **Persistent depressive symptoms despite existing therapy** • **Cognitive impairment** relative to demographic norms	• **Cogstate CTB attentional composite** (attention and working memory)	• Montgomery-Åsberg Depression Rating Scale (**MADRS**) • **Executive Function** Cognitive Composite • **Memory Function** Cognitive Composite	• **Australian trial sites** • **Actinogen "hands-on" operational model** • **First patient enrollment planned for 2022**

Involving the right people

Leadership strengthened

Extensive drug development and commercial experience

Experienced Board of Directors...

Dr. Geoff Brooke

Chairman

MBBS; MBA

- **30+ years experience** in the healthcare investment industry
- Founder and MD of Medvest Inc and GBS Ventures, Chairman of Cynata Therapeutics, Board Member of Acrux

Dr. George Morstyn

Non-Executive Director

MBBS; PhD; FRACP; MAICD

- **25+ years experience** in biotech investment and drug development
- Board member of Cancer Therapeutics and Symbio

Mr. Malcolm McComas

Non-Executive Director

BEc, LLB; FAICD; SF Fin

- **25+ years experience** in the financial services industry
- Chairman of Pharmaxis and Fitzroy River Corporation

…with a talented management team in place

Dr. Steven Gourlay

CEO & MD

MBBS; FRACP; PhD; MBA

- **30+ years experience** in development of novel therapeutics
- Former founding CMO at US-based Principia Biopharma Inc

See full team and bios at: https://actinogen.com.au/our-company/#about-us

Jeff Carter

Chief Financial Officer

B. Fin Admin; M. App. Fin; CA

Tamara Miller

SVP Product Development

M.Med Sci; BSc; MSc; PMP; CPPM

Dr Paul Rolan

Chief Medical Officer

MD, FRACP

Cheryl Townsend

VP Clinical Operations

RN, M Health Law

Dr Christian Toouli

Head of Business Development

PhD; GAICD

Michael Roberts

Investor Relations

International cognition clinical advisors

Global thought leaders in trials for assessment of cognition in dementia and depression

Prof. John Harrison

Metis Cognition Ltd

- Expert psychologist with a special interest in cognition
- Chartered psychologist with two PhDs and author/co-author of more than 80 books and scientific articles
- Principal Consultant at Metis Cognition, which advises on selection and integration of cognitive testing into therapeutic development programs

Dr Dana C. Hilt

FREQUENCY THERAPEUTICS

- 25+ years of drug development experience, primarily of Central Nervous System (CNS) drugs
- Deep experience in Phases 1 to 4 drug development
- CMO at Frequency Therapeutics and has held senior management positions as Chief Medical Officer at various pharmaceutical companies

Dr Christina Kurre Olsen

ORPHAZYME

- 20+ years research expertise in neuroscience, neuropsychopharmacology, CNS therapeutics and monoclonal antibody immunotherapy
- Strong hands-on knowledge across drug development value chain and a passion for cognition
- Medical Director at Orphazyme A/S

Prof. Paul Maruff

Cogstate

- Chief Innovation Officer at Cogstate Ltd
- Professor in Neuroscience at the Florey Institute of Neuroscience and in Psychology Monash University, Melbourne Australia
- Senior management committee of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of Alzheimer's Disease
- Involved in the development and approval of 13 new drugs that affect cognition including most recently esketamine for treatment resistant depression

A/Prof Christopher Chen

NUS National University of Singapore

- Senior Clinician-Scientist, Associate Professor at the Departments of Pharmacology and Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, and Director of the Memory Aging and Cognition Centre, National University Healthcare System.
- Major research and clinical interests are in neuroimaging, molecular biology and treatment of stroke and dementia.
- President of the Asian Society Against Dementia, Secretary-Treasurer of the Asian & Oceanian Association of Neurology.

International Scientific Advisory Boards

Thought-leader academics involved in the development of Xanamem

Alzheimer's Disease Clinical Advisory Board

Prof. Craig Ritchie

Chair

THE UNIVERSITY of EDINBURGH

- World-leading authority on dementia; senior investigator on 30+ drug trials
- Chair of the Scottish Dementia Research Consortium; Professor of the Psychiatry of Ageing' Director of the Centre for Dementia Prevention (University of Edinburgh)

Prof. Colin Masters

AO

THE FLOREY INSTITUTE OF NEUROSCIENCE & MENTAL HEALTH

THE UNIVERSITY OF MELBOURNE

The Royal Melbourne Hospital

- 35+ years research on Alzheimer's Disease and other neurodegenerative diseases
- Laureate Professor of Dementia Research and Head, Neurodegeneration Division at The Florey Institute (UniMelb)

Prof. Jeffrey Cummings

Cleveland Clinic

- World-renowned Alzheimer's researcher and leader of clinical trials
- MD, ScD; Founding Director of the Cleveland Clinic Lou Ruvo Center for Brain Health
- Recognised for his work through various awards

Scientific Advisory Board

Prof. Jonathan Seckl

THE UNIVERSITY of EDINBURGH

- Undertaken extensive research in endocrinology
- Senior VP at the university of Edinburgh; Chaired Panels for MRC, Innovate UK and Wellcome Trust
- MBBS UCL, PhD (London)

Prof. Brian Walker

Newcastle University

- 20+ years research in the area of disease
- Extensive experience advising for pharmaceutical R&D
- Pro Vice Chancellor for Research Strategy & Resources at Newcastle University, UK

Prof. Scott Webster

THE UNIVERSITY of EDINBURGH

- Chair of Medicines at the Centre of Cardiovascular Science, University of Edinburgh
- Former positions across both biotech and academia
- Founder and Chief Scientific Officer at Kynos Therapeutics

Forward planning for marketing approvals

Forward planning for marketing approvals



Commercial manufacturing

Regulatory nonclinical studies

Clinical pharmacology studies

Creating value from partnerships

Creating value from partnerships

Interacting with patient groups & granting bodies



Academic collaborations and publications

Exploring regional & global partners

Aligning plans with regulators like the US FDA

Xanamem timeline & catalysts

Actinogen

2022

- **Multiple partnering presentations of Phase 2a results**
- November **CTAD XanaMIA presentation**
- **Enrollment for XanaCIDD** trial in Depression
- Key global **regulatory submissions** in AD with FDA, EMA, other

2023

- **XanaMIA Phase 2b** enrollment starts H1
- **XanaCIDD** enrollment ± results
- **Presentations & publications**

2024

- XanaMIA **Phase 2b results**
- **Expand Depression** program
- **Expand Alzheimer's Disease** program

Questions

Thank you

If you have any questions following the AGM please contact:

Dr. Steven Gourlay
CEO & Managing Director
P. +61 2 8964 7401
E. steven.gourlay@actinogen.com.au

Michael Roberts
Investor Relations
M. +61 423 866 231
E. michael.roberts@actinogen.com.au

Appendix

Selected glossary 1

11β-HSD1 11 beta HydroxySteroid Dehydrogenase-1 enzyme

Aβ Amyloid beta – a type of amyloid protein associated with Alzheimer's Disease, 42 and 40 are different forms

ACTH Adrenocorticotropic hormone that regulates blood levels of cortisol

ADAS-Cog Alzheimer's Disease Assessment Score - Cognition

ApoE4 Apoprotein genotype associated with genetic risk of Alzheimer's Disease

ATN Amyloid, Tau, Neurodegeneration

Clinical scales Measure how a patient feels, performs and functions

CDR-SB Clinical Dementia Rating "Sum of Boxes" scale measuring cognition and function on an 18-point scale (high worse)

CNS Central nervous system

CSF Cerebrospinal fluid

CTAD Clinical Trials on Alzheimer's Disease (conference)

CTB Cognitive Test Battery of computerized tests

Double-blind Investigators, participants and company do not know who has active vs placebo treatment during a trial

EMA European Medicines Agency

FDA US Food & Drug Administration

Filament A Filament protein believed to relate to amyloid toxicity

GFAP Glial Fibrilliary Acidic Protein – a marker of microglial cell activation in the brain

IDSST International Digit Symbol Substitution Test of cognition

Selected glossary 2

IQCODE Informant Questionnaire on Cognitive Decline in the Elderly

MCI Mild Cognitive Impairment – memory, executive function deterioration with retained functional abilities

MDD Major Depressive Disorder

MMSE Mini Mental State Examination – a 30-point scale of simple questions to assess mental abilities

NfL Neurofilament Light – a nerve protein in the brain and rest of the body too

NIA-AA National Institutes of Aging and Alzheimer's Association

NMDA a type of receptor for glutamate in the brain

NPI Neuropsychiatric Inventory to assess psychiatric symptoms

NTB a Neurologic Test Battery, in this presentation one designed to measure executive function aspects of cognition

PET Positron Emission Tomography – a type of body scan

Placebo controlled Non-active treatment for double-blind design

p-Tau181 or 217 AD biomarker of phosphorylated Tau protein

QPCT Glutaminyl-peptide cyclotransferase is an enzyme proposed to create toxic amyloid species

RAVLT Rey Auditory Visual Learning Test

RBANS Repeatable Battery for the Assessment of Neuropsychological Status (a test of mental abilities)

ROC AUC Receiver Operating Curve Area Under the Curve (1.0 ideal) – a type of statistical test to compared two methods of measurement

Tau – a brain protein

Ttau – total tau levels including both phosphorylated and non-phosphorylated tau

Selected recent announcements and presentations

14 OCT 2022	Annual Report to Shareholders
10 OCT 2022	Large clinical benefit on FDA-approved measurement of cognition and function in patients with Alzheimer's Disease
10 OCT 2022	ACW clinical biomarker study webcast presentation
10 OCT 2022	ACW announces positive Alzheimers Disease clinical results
25 AUG 2022	Actinogen FY22 Results - Accelerating Clinical Development
3 AUG 2022	Actinogen Clinical Trials Science Forum webcast recording
3 AUG 2022	Actinogen Clinical Trials Science Forum presentation slides
4 MAY 2022	Actinogen trial results & strategic update presentation
4 MAY 2022	Actinogen prioritizes Alzheimers Disease & Depression
27 APR 2022	XanaMIA Part A Trial positive topline results for Xanamem webcast
27 APR 2022	ACW positive XanaMIA results webcast slide presentation
27 APR 2022	ACW announces positive XanaMIA results for Xanamem
20 DEC 2021	Capital Raising Completion
25 NOV 2021	Strategic Update & Capital Raising Investor Presentation
25 NOV 2021	Program Expansion & Capital Raising

Clinical Dementia Rating – Sum of Boxes (CDR-SB) endpoint to assess dementia in early-stage AD

Test domain	Impairment				
	None	Questionable	Mild	Moderate	Severe
	0	0.5	1	2	3
Memory					
Orientation					
Judgment & Problem Solving					
Community Affairs					
Home & Hobbies					
Personal Care					

Score is sum of each line i.e. score between 0 and 18 (0 = normal)